NRG EAY191-N2

Primary Category:

Treatment Protocols

Disease Category:

Breast, Breast Metastatic

Status:

New, Open

Phase 2 Trial of Fulvestrant and Binimetinib in Patients with Hormone Receptor-Positive Metastatic Breast Cancer with a Frameshift or Nonsense Mutation or Genomic Deletion in NF1: A ComboMATCH Treatment Trial

NCT#05554354

(See required screening study ECOG-ACRIN EAY191)